SG Americas Securities LLC Sells 8,001 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

SG Americas Securities LLC decreased its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 69.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,552 shares of the company’s stock after selling 8,001 shares during the period. SG Americas Securities LLC’s holdings in Axsome Therapeutics were worth $301,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Bank of Montreal Can bought a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $849,000. The Manufacturers Life Insurance Company lifted its position in shares of Axsome Therapeutics by 4.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,901 shares of the company’s stock valued at $1,844,000 after acquiring an additional 999 shares during the period. Algert Global LLC bought a new position in Axsome Therapeutics during the second quarter worth $250,000. Creative Planning grew its holdings in Axsome Therapeutics by 15.9% in the second quarter. Creative Planning now owns 8,365 shares of the company’s stock worth $673,000 after purchasing an additional 1,149 shares during the period. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Axsome Therapeutics in the second quarter valued at $27,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $112.92 on Wednesday. The company has a 50-day simple moving average of $94.09 and a two-hundred day simple moving average of $91.27. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The firm has a market capitalization of $5.47 billion, a PE ratio of -17.29 and a beta of 1.05. Axsome Therapeutics, Inc. has a one year low of $64.11 and a one year high of $113.33.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the previous year, the company posted ($1.32) earnings per share. On average, analysts anticipate that Axsome Therapeutics, Inc. will post -4.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AXSM. Needham & Company LLC reissued a “buy” rating and set a $133.00 price objective on shares of Axsome Therapeutics in a research report on Monday, January 13th. Truist Financial increased their price target on Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Monday. HC Wainwright boosted their price objective on Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a report on Friday, January 31st. Royal Bank of Canada reiterated an “outperform” rating and issued a $139.00 target price on shares of Axsome Therapeutics in a report on Wednesday, January 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $121.00 price target on shares of Axsome Therapeutics in a research report on Thursday, December 12th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $134.00.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.